In UAB's Division of Neurosurgery, Corinne E. Griguer, PhD and her research team is searching for potential therapeutic targets in malignant glioma. A recent recipient of a Research Project Grant, her research interests include exploring the bioenergetic pathways involved in the development and progression of malignant glioma. Patient chemoresistance to temozolomide (TMZ), the frontline drug of choice to treat glioblastoma multiforme, limits treatment options. Griguer and her colleagues at the Southern Research Institute and University of Geneva have determined that increased cytochrome c oxidase (CcO) activity is associated with TMZ resistance in glioblastoma multiforme. In the future, analysis of CcO activity in gliomas may be used to predict overall survival and progression free survivals in patients with malignant glioma. CcO activity may serve as a target for small molecule inhibitiors that could be used to block acquisition of chemoresistance in glioma. Reversing TMZ insensitivity may lead to improved outcomes in patients with GBM.

Dr. Griguer's publications

Committed to high-quality, compassionate neurosurgical care

Research

Our faculty is comprised of surgeon-scientists as well as dedicated researchers who strive to advance the field of neurosurgery through cutting-edge clinical and basic science research. We are actively translating discoveries into new potential treatment options for patients.

Education

We are committed to training the next generation of neurosurgeons through our residency and fellowship programs. Our graduates consistently achieve desired positions throughout the field of neurosurgery, both in academics and private practice. 

Patient Care

Our neurosurgeons are experts in the treatment of brain tumors, neurovascular conditions, spinal disorders, functional disorders, and pediatric conditions. The depth and breadth of our faculty's experience allow us to deliver outstanding care for the full spectrum of neurosurgical disorders.   

Upcoming Events